Biotech Models, Part I: Near-Term Strategies
As biotech valuations turn south, VCs are searching for financeable models for new companies. In Part I of a two-part article, we examine near-term models. The message: Choose distribution or research, but not both at the same time.
You may also be interested in...
The US firm gets development and co-commercial rights to MORAb-202 for $650m up front. BMS joins AstraZeneca, Merck & Co. and Gilead in recent ADC deal-making.
The recently concluded BIO annual meeting included several sessions focused on the practice of business development. In this extra edition of our BIO 2021 notebook, Scrip collected observations about best practices for partnerships.
The company’s rollout plans for Ayvakit appear similar to its approach when it marketed the drug for GIST, with an education plan to help boost sales.